UNSPSC 51162717: Guaiacol carbonate

This classification denotes an expectorant with the molecular formula C15H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q71XPQ6R29, chemically known as phenol, 2-methoxy-, carbonate (2:1) (9ci) but more generally known as guaiacol carbonate, which bears US NIH Compound Identifier 11104. European Medicines Agency schedules Guaiacol carbonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14028MIG.

Most nations, for tariff and trade purposes, schedule guaiacol carbonate under HS 29095000 and SITC 51617. As of Q4 2014, GUAIACOL CARBONATE remains US FDA's Preferred Term for this commodity. Guaiacol carbonate bears US NLM identifiers UMLS ID C0771805 and NCI Concept Code C76056. SMILES: COC1CCCCC1OC(=O)OC2CCCCC2OC.

UNSPSC 51162717 Guaiacol carbonate is a Commodity code that in recent state and local procurement activity covers pharmaceutical and medical products supplied to correctional and public health facilities. The recent opportunities tagged to this code show state and local buyers procuring parenteral products—including intravenous solutions, total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) preparations, and naloxone—for healthcare delivery in detention settings and community health initiatives. Work under the code spans product supply with associated delivery logistics, pharmacological expertise in preparation and monitoring, and compliance with strict regulatory frameworks governing controlled substances and medical products.

State corrections departments and county health authorities are the primary issuing bodies. The Washington State Department of Corrections (RFQQK13020, RFQ, due October 7, 2026) solicited parenteral products and services for eight correctional facilities across three regions with delivery requirements as tight as 24 hours for customized PN preparations and 8 hours for standard parenteral stock, selecting up to three contractors per region for an initial term through June 30, 2030. Seminole County, Florida (IFB60459723LAS, IFB) procured 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to its Community Health Building. Activity is visible in Washington and Florida; the source does not support broader geographic characterization. Both opportunities required compliance with state-level set-asides and preferences where applicable and strong insurance and employee-vetting protocols.